Your browser doesn't support javascript.
Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.
Elkhalifa, Dana; Rayan, Menatallah; Negmeldin, Ahmed T; Elhissi, Abdelbary; Khalil, Ashraf.
  • Elkhalifa D; Department of Pharmacy, Aspetar Orthopedic and Sports Medicine Hospital, Doha, Qatar.
  • Rayan M; Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar.
  • Negmeldin AT; Department of Pharmaceutical Sciences, College of Pharmacy and Thumbay Research Institute for Precision Medicine, Gulf Medical University, Ajman, United Arab Emirates; Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Elhissi A; Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar; Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar; Office of the Vice President for Research and Graduate Studies, Qatar University, Doha, Qatar.
  • Khalil A; Department of Pharmaceutical Sciences, College of Pharmacy, QU Health, Qatar University, Doha, Qatar; Biomedical and Pharmaceutical Research Unit, QU Health, Qatar University, Doha, Qatar.
Biomed Pharmacother ; 145: 112385, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1565522
ABSTRACT
Chemically modified mRNA represents a unique, efficient, and straightforward approach to produce a class of biopharmaceutical agents. It has been already approved as a vaccination-based method for targeting SARS-CoV-2 virus. The COVID-19 pandemic has highlighted the prospect of synthetic modified mRNA to efficiently and safely combat various diseases. Recently, various optimization advances have been adopted to overcome the limitations associated with conventional gene therapeutics leading to wide-ranging applications in different disease conditions. This review sheds light on emerging directions of chemically modified mRNAs to prevent and treat widespread chronic diseases, including metabolic disorders, cancer vaccination and immunotherapy, musculoskeletal disorders, respiratory conditions, cardiovascular diseases, and liver diseases.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / Vaccines, Synthetic / Genetic Therapy / Chronic Disease / Pandemics / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Immunotherapy Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2021.112385

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: RNA, Messenger / Vaccines, Synthetic / Genetic Therapy / Chronic Disease / Pandemics / SARS-CoV-2 / COVID-19 / MRNA Vaccines / Immunotherapy Type of study: Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Biomed Pharmacother Year: 2022 Document Type: Article Affiliation country: J.biopha.2021.112385